Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Langdon

Showing results (101-110 of 180) with videos related to

Pageof 18
Sort By:
Oncotarget|December 20, 2015
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancerRui Huang, Simon P Langdon, Matthew Tse, et al.
Peptides|January 1, 1997
Processing of [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P in xenograft bearing Nu/Nu miceD A Jones, A J MacLellan, J Cummings, et al.
Biochemical Pharmacology|October 15, 1983
The formation and metabolism of N-hydroxymethyl compounds--IV. Cytotoxicity and antitumour activity of N-hydroxymethylformamide, a putative metabolite of N-methylformamide (NSC 3051)P G Cooksey, E N Gate, A Gescher, et al.
Cancer Research|March 31, 2001
Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancerL M Gilmour, K G Macleod, A McCaig, et al.
Frontiers in Oncology|May 7, 2024
RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancerSarah J Taylor, Robert L Hollis, Charlie Gourley, et al.
British Journal of Cancer|September 1, 1992
12-O-tetradecanoylphorbol 13-acetate induced differentiation in human lung squamous carcinoma cellsG J Rabiasz, S P Langdon, L Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancerGraeme Walker, Kenneth MacLeod, Alistair R W Williams, et al.
Plos One|September 13, 2011
Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapyDana Faratian, Andrew H Sims, Peter Mullen, et al.
BMC Cancer|March 12, 2016
Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft modelsAntonis Koussounadis, Simon P Langdon, Inhwa Um, et al.
Oxidative Medicine and Cellular Longevity|February 8, 2018
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and ErlotinibIbrahim H Kankia, Hilal S Khalil, Simon P Langdon, et al.
Pageof 18

Showing results (101-110 of 180) with videos related to

Sort By:
Pageof 18
Oncotarget|December 20, 2015
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancerRui Huang, Simon P Langdon, Matthew Tse, et al.
Peptides|January 1, 1997
Processing of [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P in xenograft bearing Nu/Nu miceD A Jones, A J MacLellan, J Cummings, et al.
Biochemical Pharmacology|October 15, 1983
The formation and metabolism of N-hydroxymethyl compounds--IV. Cytotoxicity and antitumour activity of N-hydroxymethylformamide, a putative metabolite of N-methylformamide (NSC 3051)P G Cooksey, E N Gate, A Gescher, et al.
Cancer Research|March 31, 2001
Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancerL M Gilmour, K G Macleod, A McCaig, et al.
Frontiers in Oncology|May 7, 2024
RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancerSarah J Taylor, Robert L Hollis, Charlie Gourley, et al.
British Journal of Cancer|September 1, 1992
12-O-tetradecanoylphorbol 13-acetate induced differentiation in human lung squamous carcinoma cellsG J Rabiasz, S P Langdon, L Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancerGraeme Walker, Kenneth MacLeod, Alistair R W Williams, et al.
Plos One|September 13, 2011
Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapyDana Faratian, Andrew H Sims, Peter Mullen, et al.
BMC Cancer|March 12, 2016
Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft modelsAntonis Koussounadis, Simon P Langdon, Inhwa Um, et al.
Oxidative Medicine and Cellular Longevity|February 8, 2018
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and ErlotinibIbrahim H Kankia, Hilal S Khalil, Simon P Langdon, et al.
Pageof 18